CoChat
Sign Up
Cited by 235Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic DiseasesPeroxisome Proliferator-Activated Receptors

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

Hirose, Hiroshi, Kawai, Toshihide, Yamamoto, Yukihiro, Taniyama, Matsuo, Tomita, Motowo, Matsubara, Koichi, Okazaki, Yasunori, Ishii, Tatsuya, Oguma, Yuko, Takei, Izumi, Saruta, Takao·2002·Metabolism
DOI 10.1053/meta.2002.30506
Open this paper in CoChat — free account

Abstract

The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 +/- 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 +/- 14 to 101 +/- 10 mm Hg), FPG (8.6 +/- 1.4 to 7.0 +/- 1.0 mmol/L), serum insulin (54 +/- 11 to 30 +/- 8 pmol/L, P <.01 for all), and HbA1c (6.7 +/- 0.8 to 6.1% +/- 0.6%, P =.013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 +/- 3.2 to 27.0 +/- 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 +/- 24 to 138 +/- 24 mg/dL) and SAT (155 +/- 69 to 179 +/- 81cm2, P <.05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 +/- 1.7 to 14.4 +/- 2.1 microg/mL, P =.005). VAT tended to increase (165 +/- 38 to 180 +/- 46 cm2) and VAT/SAT ratio tended to decrease (1.2 +/- 0.3 to 1.1 +/- 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level.

Overview

Integrity signals

Registry

Crossref · 10.1053/meta.2002.30506

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 235

Related

See all

Metadata

Authors
Hirose, H., Kawai, T., Yamamoto, Y., Taniyama, M., Tomita, M., Matsubara, K., Okazaki, Y., Ishii, T., Oguma, Y., Takei, I., & Saruta, T.
Affiliations
SHOWA Medical University (JP)
ORCID
Venue
Metabolism
Publisher
Elsevier BV
Published
2002-03
Volume
51
Issue
3
Pages
314-317
ISSN
0026-0495 (ISSN-L)
DOI
10.1053/meta.2002.30506
OpenAlex
W2020949125
Cited by
235
References
30
Citations by year
2025: 2 · 2022: 2 · 2021: 8 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 5 · 2016: 5 · 2015: 4 · 2014: 9 · 2013: 7 · 2012: 6
FWCI
18.46
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
pioglitazone, type 2 diabetes, adiponectin, body fat distribution, visceral adipose tissue, subcutaneous adipose tissue, insulin, HbA1c, lipid profile, sulfonylureas, Japanese men, thiazolidinediones, atherosclerosis risk factors, blood pressure, body mass index
MeSH terms
Pioglitazone, Adipose Tissue, Adult, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Japan, Male, Middle Aged, Proteins, Thiazoles, Time Factors, Intercellular Signaling Peptides and Proteins, Asian People, Thiazolidinediones, Adiponectin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review